oxazoles has been researched along with pioglitazone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brosnan, CF; Dumitrescu-Ozimek, L; Feinstein, DL; Galea, E; Gavrilyuk, V; Heneka, MT; Landreth, GE; Pershadsingh, HA; Weinberg, G; Whitacre, CC | 1 |
| Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE | 1 |
| Bonev, AD; Eckman, DM; Gomez, MF; Heppner, TJ; Nelson, MT; Petkov, GV | 1 |
| Brown, KK; Carrick, KM; Chen, L; Clifton, LG; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Beckey, C; Parra, D; Thomas, T | 1 |
| Ashton, TT; Baines, D; Bisi, J; Blazer-Yost, BL; Brown, KK; Harrington, W; Kalsi, K; Maurio, FP; Murray, D; Nofziger, C; Smith, CD; West, TA | 1 |
| Chognot, C; Henry, RR; Herz, M; Lincoff, AM; Mudaliar, S; Rabbia, M | 1 |
| Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K | 1 |
| Chen, X; Fan, L; Su, XY; Tang, XM; Yan, JF; Yang, DC; Zhang, WY; Zhang, YX; Zhou, ZW | 1 |
| Akiyama, TE; Berger, JP; Castriota, G; Chang, CH; Chen, Y; Doebber, TW; Einstein, M; Lau, F; Li, Y; Liu, K; Liu, W; McCann, ME; McKeever, B; McNamara, L; Meinke, PT; Mosley, RT; Wang, C; Wood, HB; Wu, M; Zhou, G | 1 |
| Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Blander, G; Bobadilla, M; Catlett, NL; Deehan, R; Edgar, A; Elliston, KO; Haefliger, C; Ladd, W; Maerz-Weiss, P; Mizrahi, J; Steiner, G; Wong, B; Wright, MB | 1 |
| Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P | 1 |
| Byun, JH; Hah, YS; Hwang, SC; Joo, HH; Kang, YH; Kim, JW; Park, BW; Rho, GJ; Sung, IY; Woo, DK | 1 |
| Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D | 1 |
| Aghaei, HN; Dehpour, AR; Ebrahimi, A; Gholizadeh, R; Gooshe, M; Mousavizadeh, K; Payandemehr, B; Rahimian, R; Varastehmoradi, B | 1 |
4 trial(s) available for oxazoles and pioglitazone
| Article | Year |
|---|---|
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Topics: Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Safety; Single-Blind Method; Thiazolidinediones; Thiophenes; Treatment Outcome | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain | 2009 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes | 2014 |
16 other study(ies) available for oxazoles and pioglitazone
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Female; Glycoproteins; Humans; Hypoglycemic Agents; I-kappa B Proteins; Ligands; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxazoles; Peptide Fragments; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Remission Induction; Spinal Cord; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2002 |
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine | 2004 |
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
Topics: Algorithms; Animals; Barium; Benzophenones; Blood Pressure; Calcium Channels; Electrophysiology; Female; Hypoglycemic Agents; In Vitro Techniques; Membrane Potentials; Mesenteric Arteries; Muscle Cells; Muscle Tonus; Muscle, Smooth, Vascular; Oxazoles; Patch-Clamp Techniques; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tyrosine; Vasodilation | 2005 |
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Topics: Adiponectin; Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Binding Proteins; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Obesity; Oxazoles; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Thiazolidinediones; Tyrosine | 2004 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Pioglitazone; Thiazolidinediones; United States | 2005 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones | 2006 |
PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.
Topics: Animals; Biological Transport; Cell Line; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Dogs; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Kidney; Ligands; Models, Animal; Oxazoles; Pioglitazone; PPAR gamma; RNA, Messenger; Signal Transduction; Thiazolidinediones; Tyrosine; Vasopressins | 2009 |
[Synthesis and preliminary evaluation of antidiabetic activity of 4-(3-(4-bromophenyl)-3-oxo-1-arylpropylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide].
Topics: Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Molecular Structure; Oxazoles; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Response Elements; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones | 2009 |
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Topics: Animals; Benzimidazoles; Binding Sites; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dimethadione; Drug Partial Agonism; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Mice; Models, Molecular; Mutagenesis; Nuclear Receptor Coactivators; Oxazoles; Pioglitazone; PPAR gamma; Protein Conformation; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2011 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Topics: Alkanesulfonates; Cells, Cultured; Fenofibrate; Hepatocytes; Humans; Oxazoles; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes | 2012 |
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Thiazolidinediones; Urinary Bladder Neoplasms | 2012 |
Cultured human periosteal-derived cells have inducible adipogenic activity and can also differentiate into osteoblasts in a perioxisome proliferator-activated receptor-mediated fashion.
Topics: Benzamides; Cell Differentiation; Cells, Cultured; Humans; Osteoblasts; Oxazoles; Periosteum; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; PPAR gamma; Pyridines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Tyrosine | 2014 |
Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Topics: Anilides; Animals; Anticonvulsants; Benzoxazines; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Male; Mice; Morpholines; Naphthalenes; Oxazoles; Pentylenetetrazole; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Seizures; Thiazolidinediones; Tyrosine | 2015 |